Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients.
Botta C, Barbieri V, Ciliberto D, Rossi A, Rocco D, Addeo R, Staropoli N, Pastina P, Marvaso G, Martellucci I, Guglielmo A, Pirtoli L, Sperlongano P, Gridelli C, Caraglia M, Tassone P, Tagliaferri P, Correale P.
Botta C, et al. Among authors: barbieri v.
Cancer Biol Ther. 2013 Jun;14(6):469-75. doi: 10.4161/cbt.24425.
Cancer Biol Ther. 2013.
PMID: 23760488
Free PMC article.